Skip to main content

cobicistat

Generic: COBICISTAT·Brand: COBICISTAT, Evotaz, Genvoya, Prezcobix, Stribild, Symtuza, TYBOST, Tybost

cobicistat: 4 clinical trials tracked.

cobicistat evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about cobicistat, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 3 study sponsors
Clinical Trials (4)

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
Terminated

Primary endpoint: Number of Women Who Meet Area Under the Curve (AUC) Target in Plasma (Component 1)

Observational205 enrolledStarted 2021-09Completion 2025-0723 sites · Brazil, India, Kenya, Puerto Rico…National Institute of Allergy and Infectious Diseases (NIAID)

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

NCT04065399·Phase 1/Phase 2·SNDX
Recruiting

Primary endpoint: Number of participants with dose-limiting toxicities (DLTs) (Phase 1)

Interventionalopen447 targetStarted 2019-11Completion 2027-1250 sites · Australia, Canada, France, Germany…Syndax Pharmaceuticals

A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03480646·Phase 1/Phase 2·CNST
Completed

Primary endpoint: Efficacy: Best Objective Response Rate Percent by Treatment Group

InterventionalRandomizedopen175 enrolledStarted 2017-11Completion 2021-0241 sites · United StatesConstellation Pharmaceuticals

A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants

NCT02016924·Phase 2/Phase 3·GILD
Active, not recruiting

Primary endpoint: Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFV

Interventionalopen133 targetStarted 2014-01Completion 2027-0323 sites · Argentina, South Africa, Thailand, Uganda…Gilead Sciences